hypertrophic cardiomyopathy remains stable on a beta-blocker, and he developed no new orthopedic problems than those originally defined. VI-1 remains healthy and has had a normal daughter. VI-3 also remains healthy and has a normal son. The proband's affected uncle, V-7, died at 48 years of age from heart failure. The mother of the proband who had minor features of the disorder, V-2, is being evaluated for a myopathic syndrome associated with a polyneuropathy.
Identification of the Gene and the Mutation

Genome-Wide SNP Analysis
A genome-wide 250K NspI Affymetrix single-nucleotide polymorphism (SNP) microarray genotype analysis (Affymetrix, CA) analysis was performed on 3 affected males (Figure 1 , pedigree members V-7, V-12, and VI-2) at the Microarray facility at University of California, Los Angeles. SNP microarray gene chip data were subsequently analyzed with dCHIP software (http://www.hsph.harvard. edu/cli/complab/dchip/).
Exome Sequencing and Bioinformatics Analysis
Whole-exome sequencing was performed at Beijing Genomics Institute; Shenzhen, China, on 1 affected male (patient VI-2; Figure 1 ). Briefly, the Agilent SureSelect Human All Exon Kit was used to enrich for 50 Mb of coding sequences. A capture kit restricted to the X chromosome was not available at the time when the experiment was being performed. The captured and amplified library was loaded onto an Illumina HiSeq 2000 platform for sequencing at an estimated 50X coverage. Raw reads were aligned to the human reference genome GRCh37.69 using short oligonucleotide analysis package, which was also used for variant calling. We identified regions shared by all 3 affected patients based on the genotyping array analysis and selected regions on the X chromosome that did not have a breakpoint for at least 1.5 million base pairs for further investigation in the exomic data. Variants were annotated using the software tool Variant Annotator X, 2 which queries databases such as the Ensembl Variant Effect Predictor. 3 Public population databases [dbSNP135 (http://www.ncbi.nlm.nih.gov/SNP/), 1000 Genomes Project, 4 EVS database (http://evs.gs.washington.edu/EVS)] and in-house databases were used to filter sequencing variants and identify novel single-nucleotide variants that are predicted to alter protein function
Sanger Sequencing
Sanger sequencing was conducted for validation of the variants found in candidate genes identified through whole-exome sequencing within the critical region in patient VI-2. After identifying the candidate gene, FHL1, which contained a novel splice site variant, DNA from 15 available family members were analyzed by Sanger sequencing for family segregation analysis. Sanger sequencing was also performed on cDNA from patient VI-2 to analyze the end products of splice site change. Primers were designed with the Primer3 program (primer sequences available on request). Polymerase chain reaction (PCR) products were sequenced with the BigDye Terminator 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA). Sequencing reactions were sizeseparated on the ABI Prism 3100 DNA Analyzer (Applied Biosystems, Foster City, CA), and sequence data were collected with the ABI Data Collection software version 1.1 and subsequently analyzed with the ABI DNA Sequencing Analysis version 3.6 software. The transcript of FHL1 NM_001449.4 was used for sequence alignment.
Functional Study of the Gene and Variant
Western Blot Analysis
For western blot studies, proteins were extracted from 50 mg of skeletal muscle from five normal controls and 2 disease controls (Becker muscular dystrophy and Duchenne muscular dystrophy). Protein concentrations of the supernatants were measured with the BCA Protein Assay Kit (Pierce). Samples were stored frozen at −80°C. Aliquots of protein (2 mg) were loaded onto a sodium dodecyl sulfate (SDS)polyacrylamide gel, composed of 4% stacking (0.5 mol/L Tris-HCL [pH 6.8] and 10% SDS) and 10% resolving (1.5 mol/L Tris-HCL [pH 8.8] and 12% SDS) gels. The protein was then transferred to nitrocellulose membranes for 1 hour (110 V). Nonspecific binding was blocked for 2 hours with tris-buffered saline with tween 20 (10 mmol/L Tris-HCL [pH 7.4], 140 mmol/L NaCl, and 0.1% Tween-20) containing 5% skimmed milk; this was followed by incubation with primary antibodies for 4 hours at room temperature. Rabbit polyclonal antibody anti-FHL1 (AVIVA Systems Biology) was used at a dilution of 1:5000 in tris-buffered saline with tween 20-5% skim milk. After washing, the membranes were incubated with the corresponding anti-rabbit or antimouse IgG secondary antibodies (Dako) at a dilution of 1:1000 for 1 hour at room temperature. The membranes were developed with the chemiluminescence ECL system (Pharmacia) and then exposed to autoradiographic film. Analysis of immunoreactive bands was performed semiquantitatively. The used anti-rabbit polyclonal FHL1 antibody (dilution 1:2000 AVIVA Systems Biology) recognizes the C-terminal domain of the protein and detects only FHL1A. As control maker we used caveolin-3 at 21 kDa. The antibody is only able to bind isoform FHL1A. Even though FHL1 different isoforms have common last coding exon but the C terminus actually are quite different which is demonstrated nicely in Figure 1C of review article by Cowling et al. 9
Immunohistochemistry
In brief, after fixation with 2% paraformaldehyde and blocking with 4% BSA in PBS, samples were treated with a polyclonal anti-rabbit FHL1 antiserum (dilution 1:1000 AVIVA Systems Biology) and monoclonal antimouse skeletal slow myosin antiserum (dilution 1:5000, Sigma, Germany) overnight at 4°C. After rinsing for 15 minutes in PBS, the sections were incubated with Cy3-conjugated streptavidin goat anti-rabbit serum (Jackson-Immuno Research, dilution 1:1000) and with Alexa-Fluor 488 goat antimouse serum (Invitrogen). After the sections were mounted onto slides, a Leica epifluorescent microscope with a Zeiss Axiovert imaging system was used for visualization. For comparison with normal controls, as well as limb-girdle muscular-dystrophy muscle, sections were prepared using identical procedures as described above.
RNA Isolation and Real-Time PCR
Patient myoblasts were cultured in Skeletal Muscle Cell Growth Medium Supplement (PromoCell) with 10% fetal bovine serum (GIBCO), 50 μg/mL gentamicin (GIBCO), and 7.5 mL glutamax (per 500 mL of media; GIBCO) at 37°C with 5% CO 2 . Cells were split 1:4 after reaching ≈70% confluency to avoid the generation of myotubes.
Cells were trypsinized with 0.05% trypsin-EDTA (GIBCO) and cell pellets were washed 2× with 1× Dulbecco's phosphate-buffered saline without calcium and magnesium (Life Technologies, GIBCO). RNA was extracted using RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol and eluted in 14 μL RNase free H 2 O. 800 ng RNA of each sample were transcribed using Long-Range 2Step RT-PCR Kit (Qiagen). cDNA concentrations were determined by NanoDrop measurement and 50 ng of each cDNA were then added to Fast Sybr Green Master Mix (Applied Biosystems, Life Technologies) for semiquantitative real-time PCR. All quantitative real-time PCR experiments were performed on the StepOne PLUS Real-time PCR System from (Applied Biosystems, Life Technologies). Data were analyzed by using the Step One Plus Real-time PCR software (Applied Biosystems), and data were normalized to GAPDH. Numbering of the exons corresponds with NM_001159702 (FHL1B, shown in Figure 1A ) beginning with exon 3 as first coding exon. Primers for FHL1 isoform expression analysis are listed in Table I in the Data Supplement. In general, quantification experiments were performed in triplicates for each sample, except for the expression of FHL1 A/B/C of the sample with the c.688+1G>A mutation, where because of a technical error one data set was excluded.
We performed exact Kruskal-Wallis tests to compare ΔCt values of FHL1 isoforms between the 3 groups (healthy control, Uruguay patient, and patient with a c.688+1G>A mutation). In case of significant results, we performed post hoc pairwise comparison between the healthy control and the patients with mutation using one-sided exact Mann-Whitney U tests.
Results
Hemizygosity mapping with dChip software detected an approximate 19 Mb shared disease haplotype for all 3 affected males on Xq24-q26.3, which encompasses 708 consecutive SNPs (rs1716767 [117, 442, 440 ; Xq24] to rs4829618 [136,780,188; Xq26.3]). Genomic coordinates are based on the hg19/GRCh37 genome assembly.
Based on exome sequencing data, candidate genes located within the critical region had single-nucleotide change or insertion/deletion ( Table II in the Data Supplement). All the single base pair nucleotide changes detected through exome sequencing were confirmed by Sanger sequencing. Neither the insertion nor deletion was confirmed by Sanger, which might be because of the limitation of next-generation sequencing technology on detecting insertions and deletions at the time. All the single-nucleotide changes except for a splice site variant in the FHL1 gene (c.502-2A>G) were found with high allele frequency in the population databases, indicating they are most likely benign polymorphisms. Sequencing of all available family members proved the segregation of the FHL1 gene (c.502-2A>G) splice variant in the family according to a X-chromosomal recessive inheritance pattern (Figure 1 ).
Sequencing of cDNA derived from myoblasts of the Uruguay patient VI-2 proved skipping of the entire exon 6. The resulting primary structure is identical to the protein isoform FHL1C ( Figure 2B) .
In Western blot experiments we showed that compared with a healthy control there is almost complete absence of the FHL1A protein (expected at 29 kDa) in our patients' muscle ( Figure 3A ). See Figure I in the Data Supplement for the other 4 controls and the Duchenne muscular dystrophy and Becker muscular dystrophy controls. This is consistent with the observation that we do not see any signal in the IF of tissue sections in muscle from the proband using an antibody that detects the C-terminus of FHL1A ( Figure 3B) .
We tested the expression of 3 FHL1 isoforms (FHL1A, FHL1B, and FHL1C) in myoblasts from healthy individuals (control), patients with a c.688+1G>A mutation (the donor splice site mutation seen in x-linked myopathy with postural muscle atrophy [XMPMA] patients), and the Uruguay patient (proband VI-2). By using primers that span the exon junction of exon 5/6 we were also able to prove that exon 6 is missing in our patients' myoblasts, and thus, the expression of isoform A and B is markedly decreased. The expression of isoform FHL1C, in which exon 6 and 7 are missing, is highly increased in XMPMA and Uruguay patients. Interestingly, compared with the expression in the XMPMA patient, the level of FHL1C in the Uruguay patient is almost 4-fold increased. Exact Kruskal-Wallis tests were significant for all isoforms (ie, P=0.01, P=0.0035, and P=0.05 for FHL1A/B/C (exons 3 and 4), FHL1C (exons 5-8), and FHL1A/B (exons 5 and 6), respectively). All post hoc onesided pairwise comparisons between the healthy control and the Uruguay patient were significant. Post hoc one-sided pairwise comparisons between the healthy control and the patient with c.688+1 mutation were significant for FHL1C (exons 5-8) and FHL1A/B (exons 5 and 6; Figure 4 ).
Discussion
In this study, we identified FHL1 as the causative gene for the rare X-linked Mendelian disorder, Uruguay syndrome, characterized in a previous publication, 1 utilizing identityby-descent mapping, exome sequencing, and further genetic and expression studies. The c.502-2A>G splice site mutation in FHL1 identified in Uruguay syndrome patients causes the skipping of exon 6 resulting in an isoform identical to FHL1C ( Figure 2B ). The abundance of isoform FHL1C in the absence of FHL1A and FHL1B may explain the skeletal and cardiac muscle anomalies seen in Uruguay patients.
Four-and-a-half Lin11, Isl-1, and Mec-3 (LIM) domain protein 1 (FHL1) encodes a transcription factor protein with highly conserved four-and-a-half tandem repeated LIM domains. The LIM domain is a protein-interaction motif and is involved in linking proteins with both the actin cytoskeleton and transcriptional machinery. Proteins containing LIM domain play important roles in various cellular processes, such as cytoskeleton organization, signal transduction, gene expression, and cell differentiation. 5 FHL1 (MIM#300163), located on Xq26.3, consists of 4 to 6 coding exons (dependent on the isoform) and is expressed in skeletal and cardiac (A and B) were used. In all patient samples there is no normal FHL1 band at 37kDa, but a minor degraded band at ≈ 28 kDa. As a loading cytoskeletal control marker at the bottom of the western blot, caveolin-3 was used with a band at 21 kDa. B. Immunohistochemistry for FHL1A. Immunohistochemistry was performed in muscles from Uruguay syndrome patient, healthy controls, and a Becker muscular dystrophy patient. In the Uruguay syndrome patient the FHL1 antibody shows no staining compared with the normal membrane staining in the muscles of both controls and the Becker muscular dystrophy patient. All internal nonmembrane bound staining is an artifact. Bars adjusted to 50 μm. muscle cells, 6 where it is suggested to play a role in sarcomere synthesis and assembly. FHL1 has been identified as the causative gene for 6 different X-linked myopathies, with patients often presenting with cardiovascular disease. 7 Different mutations in the FHL1 gene lead to different myopathies. Since 2008, there are ≈40 mutations reported in FHL1 related myopathies with a wide spectrum of clinical phenotypes. It seems that different phenotype and severity may be because of which LIM domain that FHL1 the mutation occurs and if all isoforms are affected (see review by Schessl et al 8 for more detail). Although these myopathies share some overlapping clinical features, they differ with respect to age of onset, distribution and severity of the disease (see review by Cowling et al 9 and Schessl et al 8 ). It is unclear how different FHL1 mutations lead to distinct muscle diseases.
There are at least 3 isoforms of FHL1 (FHL1A, 1B, 1C; Figure 2A ) generated by alternative splicing. These isoforms differ in primary structure, expression pattern, binding partners, and subcellular locations. The FHL1A (commonly referred as FHL1) isoform contains all exons except exon 7. The C-terminal sequence of full-length isoform FHL1B binds RBP-Jk. Isoform FHL1C, with two and a half LIM domains, skips exons 6 and 7 with a similar C-terminus as FHL1B. FHL1A is the predominant isoform in heart and skeletal muscle; FHL1B and FHL1C are also expressed at a much lower level. 6, 10 Each of the FHL1 protein isoforms seems to exhibit distinct functions. However, in striated muscle much less is known of the functions of FHL1B and FHL1C. Both proteins are hypothesized to play an important role during myogenesis via regulation of protein immunoglobulin J kappa function. 9 In previous studies, 2 splice site mutations in FHL1 have been reported: one on the splice acceptor site of exon 6, having the same location as the splice site mutation in our patient (c.502-2A>T; Pen et al 12 ) and the other one in the splice donor site of exon 6 (c.688+1G>A). 11 In both studies and the current study, the end product of the splice site mutation is identical to isoform FHL1C. As expected, the expression of FHL1A and B are decreased and FHL1C is significantly increased in all studies. 12, 13 The phenotypes of patients in these 3 reports are similar in terms of cardiac hypertrophy, but otherwise are quite different ( Table 1 for comparison). X-linked myopathy with postural muscle atrophy (XMPMA, MIM#: 300696) is a late-onset scapuloaxioperoneal myopathy disorder characterized by postural muscle atrophy with rigid spine syndrome, pseudoathleticism because of muscular hypertrophy and hypertrophic cardiomyopathy. 14 Two key features of XMPMA, namely rigid spine and postural muscle atrophy, are not seen in Uruguay patients. Uruguay syndrome has an earlier onset, skeletal deformities, and a pugilistic facial appearance, not seen in XMPMA patients. Interestingly, the expression data showed that there is significant more FHL1C in Uruguay patients than in XMPMA patients. The higher level of FHL1C in Uruguay patients may explain their more severe phenotype. The phenotype associated with the altered splicing because of the c.502-2A>T mutation (Uruguay patient has c.502-2A>G) known as Emery-Dreifuss muscular dystrophy type 6 (EDMD6) Plus phenotype is characterized by a combination of muscular atrophy, pulmonary artery hypoplasia, and facial dysmorphology. 12 The adult in their family (patient 3) has a similar facial appearance as patients affected with the Uruguay syndrome. However, EDMD plus patients develop weakness and limitations in the movement of the neck not seen in the Uruguay syndrome. Although EDMD Plus is associated with brachydactyly and wide feet, the skeletal malformations are not as severe as those seen in the Uruguay syndrome. A missense mutation in the third LIM domain of FHL1 has also been reported in a family with contracture, rigid spine, and cardiomyopathy. 15 Both gain of toxic function and loss of normal protein function mechanisms have been postulated for the pathogenesis of FHL1 associated disorders. 9 The toxic accumulation of protein aggregates (ie, Toxic gain of function) is suggested to be responsible for the diagnostic feature of severe FHL1 associated reducing body myopathy. Reducing body aggregates are observed in skeletal muscle from a few patients with XMPMA, 8, 11 however,not in EDMD Plus, or Uruguay syndrome at least by light microscopy. The majority of FHL1 mutations in EDMD patients are frameshifts, which are predicted to result in premature stop codons. These novel mRNA transcripts serve either as templates for the expression of truncated protein products or loss of expression because of nonsense mediated decay. 16 Loss of normal FHL1A protein is present in all the disorders. XMPMA and Uruguay syndrome have muscular hypertrophy and elevated FHL1C protein levels. Although FHL1C expression is also increased in EDMD, muscular hypertrophy has not been reported. Why the phenotypes of the 3 disorders are significantly different in many respects cannot be explained on the basis of gain of function because of overexpression of FHL1C, unless there is a significant difference in the amount of FHL1C protein produced among the disorders. It is interesting to note that there is a missense variant in the BCORL1 gene identified in Uruguay patient ( Table II in the Data Supplement). BCORL1 can act as a corepressor when tethered to DNA. To date, this gene has not been associated with any disease. Variants in this gene have only been found in individuals with autism and intellectual disability. Even though the variant in this gene is predicted to be deleterious by computational algorithms and this gene is expressed in heart and muscle, we are not sure how the variant in this gene can contribute to the phenotype seen in Uruguay patients or any patients with muscular disorders.
In conclusion, we have identified the FHL1 gene as the causative gene for Uruguay syndrome. Our study demonstrated that the splice site mutation of FHL1 detected in patients with Uruguay syndrome leads to abundance of isoform FHL1C and absence of other isoforms, especially FHL1A, in skeletal muscle what might explain skeletal muscle hypertrophy and cardiac dysfunction. The findings of this study have important implications for diagnostic evaluation, screening, and genetic counseling of patients (also carriers) with myopathy of an unknown genetic cause, particularly in cases where pedigree information would suggest X-linked inheritance.
